The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzheimer’s Disease.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Peptide-based compositions for Alzheimer’s Disease is a key innovation area in biosimilars
Alzheimer’s Disease (AD) is a form of dementia and the most common progressive neurodegenerative disease (ND). Although amyloid-beta (Aβ) has long been used as a potential target for managing AD, the use of peptide-based compounds is under investigation globally for the early diagnosis and treatment of AD. Studies in mouse model have demonstrated significant improvement the mice’s memory with two short peptides injected daily for five weeks. The treatment also reduced some of the disease-associated harmful physical changes in the brain.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of peptide-based compositions for Alzheimer’s Disease.
Key players in peptide-based compositions for Alzheimer’s Disease – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to peptide-based compositions
Source: GlobalData Patent Analytics
AC Immune, one of the leading players, is utilising its technology platforms SupraAntigen and Morphomer to fuel its broad and diversified pipeline of first and best-in-class assets. The company partners with pharmaceutical majors such as Genentech (Roche Group), Eli Lilly, and Janssen Pharmaceuticals (Johnson & Johnson group) to develop anti-Aβ and anti-tau antibodies using its proprietary technologies.
Roche, which is known for its cancer medicines and diagnostics, has built up its AD pipeline by collaborating with MorphoSys to develop gantenerumab, which is now in Phase III clinical trials for AD. Roche has further expanded its AD pipeline via its subsidiary, Genentech, through licensing agreements with other companies. At the same time, Genentech is developing anti-Aβ and anti-tau antibodies using AC Immune’s proprietary SupraAntigen technology platform.
In terms of application diversity, Alnylam Pharmaceuticals is the top company, followed by Proteome Sciences and Vitruvian Biomedical. By means of geographic reach, Teijin holds the top position. MorphoSys and Alnylam Pharmaceuticals are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.